Gastric inhibitory polypeptide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Gastric inhibitory polypeptide
DrugBank Accession Number
DB15217
Background

Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea).

Type
Biotech
Groups
Investigational
Synonyms
  • GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Gastric inhibitory polypeptide.
AcebutololThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Gastric inhibitory polypeptide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Gastric inhibitory polypeptide.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Gastric inhibitory polypeptide.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Gastric inhibitory polypeptide.
AlogliptinThe risk or severity of hypoglycemia can be increased when Alogliptin is combined with Gastric inhibitory polypeptide.
AmcinonideThe risk or severity of hyperglycemia can be increased when Amcinonide is combined with Gastric inhibitory polypeptide.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1O4H75S7H2
CAS number
100040-31-1

References

General References
Not Available
Wikipedia
Gastric_inhibitory_polypeptide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentDiabetes1
1CompletedTreatmentType 2 Diabetes Mellitus1
1, 2CompletedBasic ScienceDiabetes Mellitus1
Not AvailableCompletedNot AvailableCystic Fibrosis (CF)1
Not AvailableCompletedNot AvailableType 2 Diabetes Mellitus1
Not AvailableCompletedBasic ScienceMaturity-Onset Diabetes of the Young, Type 31

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 15:01 / Updated on June 12, 2020 16:53